Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Location

MS status

Recruitment Status

Phase

Drugs

Prior Immunotherapy Allowed

NCT ID

Title key word search

Date Trial Added

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Phase	Date Added	Location	Prior IO Allowed	CRC-directed	Status	Drugs	Tags
NCT ID NCT06176885	TitleEfficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer	Phase Phase 2	Date Added 2023-12-20	Location China	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs Camrelizumab	Tags MSS/ MMRp
NCT ID NCT02537418	TitleDurvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens	Phase Phase 1	Date Added 2015-09-01	Location Canada	Prior IO Allowed Yes	CRC-directed No	Status Active, not recruiting	Drugs durvalumab, Tremelimumab, Imfinzi	Tags MSS/ MMRp
NCT ID NCT02888743	TitleDurvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer	Phase Phase 2	Date Added 2016-09-05	Location Arizona, United States California, United States Connecticut, United States Florida, United States Georgia, United States Kentucky, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Missouri, United States New Jersey, United States North Carolina, United States Ohio, United States Pennsylvania, United States Tennessee, United States Virginia, United States Wisconsin, United States Canada	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs durvalumab, Tremelimumab	Tags MSS/ MMRp
NCT ID NCT03911557	TitleDurvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors	Phase Phase 2	Date Added 2019-04-11	Location Kentucky, United States	Prior IO Allowed No	CRC-directed No	Status Active, not recruiting	Drugs Durvalumab and Tremelimumab	Tags MSS/ MMRp
NCT ID NCT05479812	TitleDose Escalation Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors	Phase Phase 1	Date Added 2022-07-29	Location Arizona, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States New Jersey, United States New York, United States Oregon, United States Texas, United States	Prior IO Allowed Yes	CRC-directed No	Status Recruiting	Drugs Pembrolizumab, WTX-124	Tags MSI-H/ MMRd
NCT ID NCT03310008	TitleDose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases	Phase Phase 1	Date Added 2017-10-16	Location Belgium	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs NKR-2 cells	Tags MSS/ MMRp
NCT ID NCT05493683	TitleDisitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer	Phase Phase 2	Date Added 2022-08-09	Location China,China,China,China,China,China	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs Disitamab vedotin, Tislelizumab	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05770102	TitleDETERMINE Trial Treatment Arm 2: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition	Phase Phase 2	Date Added 2023-03-15	Location United Kingdom	Prior IO Allowed No	CRC-directed No	Status Recruiting	Drugs Atezolizumab	Tags MSI-H/ MMRd
NCT ID NCT03668431	TitleDabrafenib + Trametinib + PDR001 In Colorectal Cancer	Phase Phase 2	Date Added 2018-09-12	Location Massachusetts, United States	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs Dabrafenib, PDR001, Trametinib, Mekinist, Tafinlar	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03566355	TitleCurative Proton Beam Therapy for Patients With Lung Metastasis of Colorectal Cancer	Phase Not Applicable	Date Added 2018-06-25	Location Korea, Republic of	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs	Tags MSI-H/ MMRd, MSS/ MMRp

Showing 181 to 190 of 299 entries